London, 14 August 2023 – Resolution Therapeutics Limited (“Resolution”), a biopharmaceutical company developing macrophage cell therapies to treat advanced liver disease, today announced the appointment of Dr. Amir Hefni as Chief Executive Officer (CEO). Dr. Hefni brings almost 20 years’ experience in drug discovery and development leadership in the biotechnology and pharmaceutical industry and joins Resolution from Novartis where he was the Head of Cell & Gene Therapy. Dr. Hefni succeeds Dr. Edward Hodgkin, who, alongside his role as Managing Partner of Syncona Investment Management Limited, has served as Resolution’s CEO since the Company’s launch in August 2020. Edward will remain on the Board of Resolution as a Non-Executive Director.
Amir Hefni, Chief Executive Officer at Resolution Therapeutics
“There are currently very few options for people who develop decompensated cirrhosis of the liver. We are delighted to welcome Amir to lead Resolution. His wonderful style and experience with both cell therapies and liver disease provide a unique perspective to the team as we progress our lead programme to the clinic.” said Lisa Bright, Chair of Resolution. “I would like to thank Edward for his tremendous leadership and ongoing engagement with Resolution.”
Dr. Amir Hefni added, “I am very pleased to be joining Resolution at this exciting time. The Company’s lead program to treat chronic end-stage liver cirrhosis seeks to avoid patients undergoing a liver transplantation, a highly invasive and complex surgical procedure which is limited by complications and a shortage of donors. I look forward to working with the talented team at Resolution and progressing the Company’s macrophage cell therapy technology that has the potential to transform patients’ lives.”
“Resolution was founded In line with Syncona’s investment strategy of creating businesses around exceptional science in areas of high unmet medical need, where there is the potential to deliver a transformational impact to patients,” added Dr. Edward Hodgkin, Managing Partner of Syncona Investment Management Limited. “Amir has an exceptional track record as a global biopharma leader and his deep expertise in autologous cell therapy development and commercialisation will be invaluable in Resolution’s next stage of growth.”
During his time at Novartis Dr. Hefni was responsible for the Company’s Global Cell & Gene Therapy business including product development, manufacturing, supply chain and commercialisation. Prior to that he served as a Global Asset Head in Oncology (including hepatocellular carcinoma) at Ipsen, where he was instrumental in launching products in multiple indications, driving significant global brand growth, and developing a rich Life Cycle Management program. Previously, he held various commercials roles with Bristol-Myers Squibb (BMS) including Executive Director, US Oncology Thoracic Lead. Dr. Hefni brings a wealth of experience working across different markets including US, UK/Ireland, Switzerland and Sweden.
Dr. Hefni holds a BSc and PhD in Pharmacology from King’s College London and an MBA from Warwick Business School. He is a Board Director of Lift Biosciences and MedUniverse.
– Ends –
|+44 (0)7818 430877
Notes for Editors:
Resolution Therapeutics is a biotechnology company developing macrophage cell therapies to treat advanced liver disease. The Company is built upon more than a decade of work in the Founders’ laboratories characterising the role of macrophages in organ repair, including the liver, both in the pre-clinical and clinical settings. Resolution will discover, develop, and take to market macrophage cell therapies based on its proprietary platform of macrophage biology, cell engineering and manufacturing processes. www.resolution-tx.com